Skip to main content
Figure 1 | Molecular and Cellular Therapies

Figure 1

From: Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?

Figure 1

Advancements in genome editing facilitate stem cell-based gene therapies. In a probable scenario, human somatic cells (such as fibroblasts) will be derived from a patient and will be reprogrammed into induced pluripotent stem (iPS) cells. Genetic mutations will then be corrected using one of the recent techniques for efficient and accurate genome editing: ZFN, TALEN or CRISPR. The genetically-modified iPS cells will next be differentiated into the desired cell type (for example, cardiomyocytes) and transplanted back into the patient's body.

Back to article page